Inhibikase Therapeutics (IKT) announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT:
- Inhibikase Therapeutics, Inc. (IKT) Q4 Earnings Cheat Sheet
- Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals
- Inhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO
- Inhibikase Therapeutics Appoints Mark Iwicki as New CEO
- Inhibikase Therapeutics appoints Mark Iwicki as CEO